William F. Doyle

Insider Reports History

Entity
Individual
Signature
/s/ Amy C. Seidel, as Attorney-in-Fact for William F. Doyle
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by William F. Doyle:

Stock Role Class Num Shares Value Price $ Report Date Ownership
NovoCure Ltd Executive Chairman, Director Ordinary Shares 551K $6.97M $12.65 Aug 2, 2022 Direct
Elanco Animal Health Inc Director Common Stock 94.5K $1.4M $14.85 Nov 29, 2024 Direct
PROKIDNEY CORP. Director Director stock option (right to buy) 62.6K May 30, 2024 Direct
Minerva Neurosciences, Inc. Director Stock Option (right to buy) 2.5K Jun 10, 2022 Direct

Insider Reports Filed by William F. Doyle

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ELAN Elanco Animal Health Inc Nov 29, 2024 1 $0 4 Dec 3, 2024 Director
PROK PROKIDNEY CORP. May 30, 2024 1 $0 4 Jun 3, 2024 Director
ELAN Elanco Animal Health Inc May 21, 2024 1 $255K 4 May 23, 2024 Director
ELAN Elanco Animal Health Inc Mar 8, 2024 1 $245K 4 Mar 12, 2024 Director
ELAN Elanco Animal Health Inc Nov 30, 2023 1 $0 4 Dec 4, 2023 Director
PROK PROKIDNEY CORP. Jun 29, 2023 1 $0 4 Jul 3, 2023 Director
ELAN Elanco Animal Health Inc Nov 30, 2022 1 $0 4 Dec 2, 2022 Director
NVCR NovoCure Ltd Aug 2, 2022 1 -$58.3K 4 Aug 3, 2022 Executive Chairman, Director
PROK PROKIDNEY CORP. Jul 11, 2022 2 $0 4 Jul 13, 2022 Director
PROK PROKIDNEY CORP. Jul 11, 2022 0 $0 3 Jul 13, 2022 Director
NERV Minerva Neurosciences, Inc. Jun 10, 2022 1 $0 4 Jun 28, 2022 Director
NVCR NovoCure Ltd Mar 8, 2022 1 -$167K 4 Mar 9, 2022 Executive Chairman, Director
NVCR NovoCure Ltd Mar 3, 2022 1 $1.18M 4 Mar 7, 2022 Executive Chairman, Director
ELAN Elanco Animal Health Inc Nov 30, 2021 1 $0 4 Dec 2, 2021 Director
NVCR NovoCure Ltd Aug 2, 2021 1 -$149K 4 Aug 4, 2021 Executive Chairman, Director
NERV Minerva Neurosciences, Inc. Jun 11, 2021 1 $0 4 Jun 15, 2021 Director